Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

British Journal of Haematology

Volumn 160, Issue 2, 2013, Pages 153-170

  Collins, Peter W ^a   Chalmers, Elizabeth ^b   Hart, Daniel P ^c   Liesner, Ri ^d   Rangarajan, Savita ^e   Talks, Kate ^f   Williams, Mike ^g   Hay, Charles R ^h   Dolan, G ⁱ  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^f ROYAL VICTORIA INFIRMARY   (United Kingdom)

^g BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UKHCDO Secretariat   (United Kingdom)

Author keywords

Bypassing agents; Factor VIII IX; Haemophilia; Haemostasis; Immune tolerance induction; Inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; DESMOPRESSIN; DEXAMETHASONE; HEMOSTATIC AGENT; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RITUXIMAB; STEROID; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; BLEEDING; BRAIN HEMORRHAGE; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG MONITORING; ELECTIVE SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MUCOSAL BLEEDING; NOTE; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SOFT TISSUE BLEEDING; SURGICAL PATIENT; VASCULAR ACCESS;

BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FACTOR IX; FACTOR VIIA; FACTOR VIII; FEMALE; GREAT BRITAIN; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC TESTS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; MALE; RECOMBINANT PROTEINS; RISK FACTORS; STATE MEDICINE;

EID: 84872264793     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12091     Document Type: Note

References (132)

1. Aledort, L.M. (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. Journal of Thrombosis and Haemostasis, 2, 1700-1708.
2. Aledort, L.M., Navickis, R.J. & Wilkes, M.M. (2011a) Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. Journal of Thrombosis and Haemostasis, 9, 2180-2192.
3. Aledort, L.M., Navickis, R.J. & Wilkes, M.M. (2011b) Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII. Journal of Thrombosis and Haemostasis, 9, 2325-2327.
4. Alexander, S., Hopewell, S., Hunter, S. & Chouksey, A. (2008) Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. Journal of Pediatric Hematology/oncology, 30, 93-95.
5. Astermark, J., Berntorp, E., White, G.C. & Kroner, B.L.; MIBS Study Group. (2001) The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia, 7, 267-272.
6. Astermark, J., Donfield, S.M., DiMichele, D.M., Gringeri, A., Gilbert, S.A., Waters, J. & Berntrop, E. (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood, 109, 546-551.
7. Auerswald, G., Bidlingmaier, C. & Kurnik, K. (2012) Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients-long-term follow-up and continuing experience. Haemophilia, 18, e18-e20.
8. Batlle, J., Lopez, M.F. & Brackmann, H.H. (1999) Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia, 5, 431-435.
9. Baudo, F., Collins, P., Huth-Kuehne, A., Lévesque, H., Marco, P., Nemes, L., Pellegrini, F., Tengborn, L. & Knoebl, P.; on behalf of the EACH2 registry contributors. (2012) Management of bleeding in acquired hemophilia A (AHA): results from the European Acquired Hemophilia (EACH2) Registry. Blood, 120, 39-46.
10. Berntorp, E. (2009) Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia, 15, 3-10.
11. Berntrop, E. (2011) Importance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia, 17, 11-16.
12. Berntrop, E., Collins, P., D'Oiron, R., Ewing, N., Gringeri, A., Negrier, C. & Young, G. (2011) Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia, 17, e202-e210.
13. Beutel, K., Hauch, H., Rischewski, J., Kordes, U., Schneppenheim, J. & Schneppenheim, R. (2009) ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie, 29, 155-157.
14. Björkman, S. (2011) A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia, 17, 179-184.
15. Björkman, S., Folkesson, A. & Berntorp, E. (2007) In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia, 13, 2-8.
16. Björkman, S., Blanchette, V.S., Fischer, K., Oh, M., Spotts, G., Schroth, P., Fritsch, S., Patrone, L., Ewenstein, B.M.; Advate Clinical Program Group. & Collins, P.W. (2010) Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 8, 730-736.
17. Björkman, S., Oh, M., Spotts, G., Schroth, P., Fritsch, S., Ewenstein, B.M., Casey, K., Fischer, K., Blanchette, V.S. & Collins, P.W. (2012) Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood, 119, 612-618.
18. Blanchette, V.S., Shapiro, A.D., Liesner, R.J., Hernández Navarro, F., Warrier, I., Schroth, P.C., Spotts, G. & Ewenstein, B.M.; rAHF-PFM Clinical Study Group. (2008) Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. Journal of Thrombosis and Haemostasis, 6, 1319-1326.
19. Boekhorst, J., Lari, G.R., D'Oiron, R., Costa, J.M., Nováková, I.R., Ala, F.A., Lavergne, J.M. & van Heerde, W.L. (2008) Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia, 14, 729-735.
20. Brackmann, H.H., Oldenburg, J. & Swaab, R. (1996) Immune tolerance for the treatment of factor VIII inhibitors - twenty years of the Bonn protocol. Vox Sanguinis, 70, 30-35.
21. Bray, G.L., Gomperts, E.D., Courter, S., Gruppo, R., Gordon, E.M., Manco-Johnson, M., Shapiro, A., Scheibel, E., White, G. 3rd & Lee, M. (1994) A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood, 83, 2428-2435.
22. Carcao, M., St Louis, J., Poon, M.C., Grunebaum, E., Lacroix, S., Stain, A.M., Blanchette, V.S. & Rivard, G.E.; Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada. (2006) Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia, 12, 7-18.
23. Chalmers, E.A., Brown, S.A., Keeling, D., Liesner, R., Richards, M., Stirling, D., Thomas, A., Vidler, V., Williams, M.D. & Young, D.; Paediatric Working Party of UKHCDO. (2007) Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia, 13, 149-155.
24. Chitlur, M., Warrier, I., Rajpurkar, M. & Lusher, J.M. (2009) Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia, 5, 1027-1031.
25. Chuansumrit, A., Moonsup, Y., Sirachainan, N., Benjaponpitak, S., Suebsangad, A. & Wongwerawattanakoon, P. (2008) The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagulation & Fibrinolysis, 19, 208-211.
26. Collins, P.W., Blanchette, V.S., Fischer, K., Björkman, S., Oh, M., Fritsch, S., Schroth, P., Spotts, G., Astermark, J. & Ewenstein, B.; rAHF-PFM Study Group. (2009a) Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostasis, 7, 413-420.
27. Collins, P.W., Mathias, M., Hanley, J., Keeling, D., Keenan, R., Laffan, M., Perry, D. & Liesner, R.; UK Haemophilia Centre Doctors' Organisation. (2009b) Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostasis, 7, 787-794.
28. Cross, D.C. & Van Den Berg, H.M. (2007) Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia, 13, 111-114.
29. Curry, N.S., Misbah, S.A., Giangrande, P.L. & Keeling, D.M. (2007) Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophilia, 13, 328-330.
30. Dargaud, Y., Luddington, R., Gray, E., Negrier, C., Lecompte, T., Petros, S., Hogwood, J., Bordet, J.-C., Regnault, V., Siegemund, A. & Baglin, T. (2007) Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. British Journal of Haematology, 139, 303-309.
31. Dargaud, Y., Lambert, T. & Trossaert, M. (2008) New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia, 14(Suppl. 4), 20-27.
32. Dargaud, Y., Lienhart, A. & Negrier, C. (2010) Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood, 116, 5734-5737.
33. DiMichele, D.M. (2003) Immune tolerance therapy dose as an outcome predictor. Haemophilia, 9, 382-386.
34. DiMichele, D. (2007) Inhibitor development in haemophilia B: an orphan disease in need of attention. British Journal of Haematology, 138, 305-315.
35. DiMichele, D. (2009) The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia, 15, 320-328.
36. DiMichele, D.M. & Kroner, B.; the North American Immune Tolerance Study Group. (2002) The North American Immune Tolerance registry: practices, outcomes, outcome predictors. Thrombosis and Haemostasis, 87, 52-57.
37. DiMichele, D. & Négrier, C. (2006) A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia, 12, 352-362.
38. Eckhardt, C.L., Menke, L.A., van Ommen, C.H., van der Lee, J.H., Geskus, R.B., Kamphuisen, P.W., Peters, M. & Fijnvandraat, K. (2009) Intensive peri-operative use of factor VIII and the Arg593->Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. Journal of Thrombosis and Haemostasis, 7, 930-937.
39. Eckhardt, C.L., van der Bom, J.G., van der Naalt, M., Peters, M., Kamphuisen, Pw. & Fijnvandraat, K. (2011) Surgery and inhibitor development in haemophilia A: a systematic review. Journal of Thrombosis and Haemostasis, 9, 1948-1958.
40. Eckhardt, C., Peter, M., Peerlinck, K., Oldenburg, J., Santagostino, E., Astermark, J., Van Heerde, W., Hermans, C., Reitter-Pfoertner, S., Kamphuisen, P., Van Der Bom, J. & Fijnvandraat, K. (2012) Identification of 18 high risk mutations for inhibitor development in 2, 700 non-severe hemophilia A patients. Haemophilia, 18(Suppl. 3), 96.
41. Ewenstein, B.M., Takemoto, C., Warrier, I., Lusher, J., Saidi, P., Eisele, J., Ettinger, L.J. & DiMichele, D. (1997) Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood, 89, 1115-1116.
42. Ewing, N.P. & Kasper, C.K. (1982) In vitro detection of mild inhibitors to factor VIII in hemophilia. American Journal of Clinical Pathology, 77, 749-752.
43. Fox, R.A., Neufeld, E.J. & Bennett, C.M. (2006) Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia, 12, 218-222.
44. Franchini, M. & Lippi, G. (2010) Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review. Thrombosis and Haemostasis, 104, 931-940.
45. Freiburghaus, C., Berntorp, E., Ekman, M., Gunnarsson, M., Kjellberg, B. & Nilsson, I.M. (1999) Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia, 5, 32-39.
46. Giangrande, P.L., Wilde, J.T., Madan, B., Ludlam, C.A., Tuddenham, E.G., Goddard, N.J., Dolan, G. & Ingerslev, J. (2009) Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia, 15, 501-508.
47. Gouw, S.C., van der Bom, J.G. & Marijke van Den Berg, H. (2007a) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 109, 4648-4654.
48. Gouw, S.C., van Den Berg, H.M., le Cessie, S. & van der Bom, J.G. (2007b) Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 5, 1383-1390.
49. Gouw, S.C., Van Der Bom, J.G., Van Den Berg, H.M., Zewald, R.A., Ploos Van Amstel, J.K. & Mauser-Bunschoten, E.P. (2011) Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients. Haemophilia, 17, 275-281.
50. Gouw, S.C., van Den Berg, H.M., Oldenburg, J., Astermark, J., de Groot, P.G., Margaglione, M., Thompson, A.R., van Heerde, W., Boekhorst, J., Miller, C.H., le Cessie, S. & van der Bom, J.G. (2012) F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 119, 2922-2934.
51. Gringeri, A. (2007) VWF/FVIII concentrates in high-risk immunotolerance: the RESIST Study. Haemophilia, 13(Suppl. 5), 73-77.
52. Gringeri, A. & Mannucci, P.M. (2005) Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia, 11, 611-619.
53. Gringeri, A., Musso, R., Mazzucconi, M.G., Piseddu, G., Schiavoni, M., Pignoloni, P. & Mannucci, P.M.; RITS-FITNHES Study Group. (2007) Immune tolerance induction with a high purity von willebrand factor VIII complex concentrate in haemophilia A patients with inhibitors at high risk of poor response. Haemophilia, 13, 373-379.
54. Gringeri, A., Fischer, K., Karafoulidou, A., Klamroth, R., LópezFernández, M.F. & Mancuso, E.; European Haemophilia Treatment Standardisation Board (EHTSB). (2011) Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia, 17, 630-635.
55. Hay, C.R. & DiMichele, D.M.; for the International Immune Tolerance Study. (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood, 119, 1335-1344.
56. Hay, C.R., Ludlam, C.A., Colvin, B.T., Hill, F.G., Preston, F.E., Wasseem, N., Bagnall, R., Peake, I.R., Berntorp, E., Mauser Bunschoten, E.P., Fijnvandraat, K., Kasper, C.K., White, G. & Santagostino, E. (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thrombosis and Haemostasis, 79, 762-766.
57. Hay, C.R., Baglin, T.P., Collins, P.W., Hill, F.G. & Keeling, D.M. (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). British Journal of Haematology, 111, 78-90.
58. Hay, C.R., Brown, S., Collins, P.W., Keeling, D.M. & Liesner, R. (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. British Journal of Haematology, 133, 591-605.
59. Hay, C.R., Palmer, B., Chalmers, E., Liesner, R., Maclean, R., Rangarajan, S., Williams, M. & Collins, P.W.; United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO). (2011) Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 117, 6367-6370.
60. Hilgartner, M.W., Makipernaa, A. & DiMichele, D.M. (2003) Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia, 9, 261-268.
61. ®)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience. Haemophilia, 18, 544-549.
62. Ingerslev, J. & Sørensen, B. (2011) Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. British Journal of Haematology, 155, 256-262.
63. Iorio, A., Matino, D., D'Amico, R. & Makris, M. (2010a) Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database of Systematic Reviews, Art No.: CD, DOI:10.1002/14651858.CD004449, pub3.
64. Iorio, A., Halimeh, S., Holzhauer, S., Goldenberg, N., Marchesini, E., Marcucci, M., Young, G., Bidlingmaier, C., Brandao, L.R., Ettingshausen, C.E., Gringeri, A., Kenet, G., Knöfler, R., Kreuz, W., Kurnik, K., Manner, D., Santagostino, E., Mannucci, P.M. & Nowak-Göttl, U. (2010b) Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis, 8, 1256-1265.
65. Iorio, A., Marcucci, M. & Makris, M. (2011) Concentrate-related inhibitor risk: is a difference always real? Journal of Thrombosis and Haemostasis, 9, 2176-2179.
66. Kasper, C.K., Aledort, L.M., Counts, R.B., Edson, J.R., Frantoni, J., Green, D., Hampton, J.W., Hilgartner, M.W., Lazerson, J., Levine, P.H., McMillan, C.W., Pool, J.G., Shapiro, S.S., Shulman, N.R. & Van Eys, J. (1975) A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica, 34, 869-872.
67. Kavakli, K., Yesilipek, A., Antmen, B., Aksu, S., Balkan, C., Yilmaz, D., Kupesiz, A., Sasmaz, I., Lindgren, P. & Mesterton, J. (2010) The value of early treatment in patients with haemophilia and inhibitors. Haemophilia, 16, 487-494.
68. Kavalki, K., Makris, M., Zulfikar, B., Erhardtsen, E., Abrams, Z.S. & Kenet, G. (2006) Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. Thrombosis and Haemostasis, 95, 600-605.
69. Keeling, D., Beavis, J. & Sukhu, K. (2005) A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B. British Journal of Haematology, 128, 885.
70. Kempton, C.L. & White, G.C. (2009) How we treat a hemophilia A patient with a factor VIII inhibitor. Blood, 113, 11-17.
71. Key, N.S., Aledort, L.M., Beardsley, D., Cooper, H.A., Davignon, G., Ewenstein, B.M., Gilchrist, G.S., Gill, J.C., Glader, B., Hoots, W.K., Kisker, C.T., Lusher, J.M., Rosenfield, C.G., Shapiro, A.D., Smith, H. & Taft, E. (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thrombosis and Haemostasis, 80, 912-918.
72. Kitchen, S., Olson, J.D. & Preston, F.E. (2009) Quality in Laboratory Hemostasis and Thrombosis, 1st edn. Wiley & Blackwell, Oxford, UK, p. 202.
73. Klarmann, D., Martinez Saguer, I., Funk, M.B., Knoefler, R., von Hentig, N., Heller, C. & Kreuz, W. (2008a) Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia, 14, 44-49.
74. Klarmann, D., Martinez Saguer, I., Funk, M.B., Knoefler, R., von Hentig, N., Heller, C. & Kreuz, W. (2008b) Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia, 14, 44-49.
75. Konkle, B.A., Ebbesen, L.S., Erhardtsen, E., Bianco, R.P., Lissitchkov, T., Rusen, L. & Serban, M.A. (2007) Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis, 5, 1904-1913.
76. Kreuz, W., Ehrenforth, S., Funk, M., Auerswald, D., Mentzer, J., Joseph-Steiner, J., Beeg, T., Klarmann, D., Scharrer, I. & Kornhuber, B. (1995) Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia, 1, 24-32.
77. Kreuz, W., Mentzer, D., Auerswald, G., Becker, S. & Joseph-Steiner, J. (1996) Successful immunetolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia, 2(Suppl. 1), 19.
78. Kreuz, W., Escurich-Ettinghauser, C., Martinez, I., Mentzer, D., Figura, S. & Klarmann, D. (2000) Efficacy and safety of FVIII inhibitor bypassing activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors. Blood, 96, 265a, abs 1140.
79. Kroner, B.L. (1999) Comparison of the international immune tolerance registry and the North American Immune tolerance registry. Vox sanguinis, 77, 33-37.
80. Kurth, M., Puetz, J., Kouides, P., Sanders, J., Sexauer, C., Bernstein, J., Gruppo, R., Manco-Johnson, M., Neufeld, E.J., Rodriguez, N., Wicklund, B., Quon, D. & Aledort, L. (2011) The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. Journal of Thrombosis and Haemostasis, 9, 2229-2234.
81. Lee, M., Morfini, M., Schulman, S. & Ingerslev, J.; the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. (2001) Scientific and Standardization Committee Communication: The design and analysis of pharmacokinetic studies of coagulation factors. http://www.isth.org/default/assets/File/fviiipharmaco.pdf
82. Leissinger, C.A., Becton, D.L., Ewing, N.P. & Valentino, L.A. (2007) Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia, 13, 249-255.
83. Leissinger, C., Gringeri, A., Antmen, B., Berntorp, E., Biasoli, C., Carpenter, S., Cortesi, P., Jo, H., Kavakli, K., Lassila, R., Morfini, M., Negrier, C., Ocino, A., Schramm, W., Serban, M., Uscatescu Windyga, J., Zulfikar, B. & Mantovani, L. (2011) Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. New England Journal of Medicine, 365, 1685-1692.
84. Lenk, H. (1999) The German National Immune Tolerance Registry 1997 update. Vox Sanguinis, 77(Suppl. 1), 28-30.
85. Lewis, S.J., Stephens, E., Florou, G., Macartney, N.J., Hathaway, L.S., Knipping, J. & Collins, P.W. (2007) Measurement of global haemostasis in severe haemophilia A following factor VIII infusion. British Journal of Haematology, 138, 775-782.
86. Ludlam, C.A., Smith, M.P., Morfini, M., Gringeri, A., Santagostino, E. & Savidge, G.F. (2003) A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. British Journal of Haematology, 120, 808-813.
87. Lusher, J.M., Arkin, S., Abildgaard, C.F. & Schwartz, R.S. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New England Journal of Medicine, 328, 453-459.
88. Lusher, J.M., Lee, C.A., Kessler, C.M. & Bedrosian, C.L.; ReFacto Phase 3 Study Group. (2003) The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia, 9, 38-49.
89. Maclean, P.S., Richards, M., Williams, M., Collins, P., Liesner, R., Keeling, D.M., Yee, T., Will, A.M., Young, D. & Chalmers, E.A.; Paediatric Working Party of UKHCDO. (2011) Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia, 17, 282-287.
90. Mariani, G., Ghirardini, A. & Belloco, R. (1994) Immunetolerance in hemophilia. Principal results from the international registry. Thrombosis and Haemostasis, 72, 155-158.
91. Martinowitz, U., Livnat, T., Zivelin, A. & Kenet, G. (2009) Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia, 15, 904-910.
92. Mathias, M., Khair, K., Hann, I. & Liesner, R. (2004) Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. British Journal of Haematology, 125, 366-368.
93. Mauser-Bunschoten, E.P., Den Uijl, I.E., Schutgens, R.E., Roosendaal, G. & Fischer, K. (2012) Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia, 18, 263-267.
94. Mauser-Bunschoten, E.P., Niewenhuis, H.K., Roosendaal, G. & van Den Berg, H.M. (1995) Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood, 86, 983-988.
95. McMillan, C.W., Shapiro, S.S., Whitehurst, D., Hoyer, L.W., Rao, A.V. & Lazerson, J. (1988) The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood, 71, 344-348.
96. Miller, C.H., Platt, S.J., Rice, A.S., Kelly, F. & Soucie, J.M.; Hemophilia Inhibitor Research Study Investigators. (2012) Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. Journal of Thrombosis and Haemostasis, 10, 1055-1061.
97. Morfini, M., Auerswald, G., Kobelt, R.A., Rivolta, G.F., Rodriguez-Martorell, J., Scaraggi, F.A., Altisent, C., Blatny, J., Borel-Derlon, A. & Rossi, V. (2007) Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia, 13, 502-507.
98. Nakar, C., Cooper, D.L. & DiMichele, D. (2010) Recombinant activated actor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Haemophilia and Thrombosis Research Society Registry (2004-2008). Haemophilia, 16, 625-631.
99. Obergfell, A., Auvinen, M.K. & Mathew, P. (2008) Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia, 14, 233-241.
100. Oldenburg, J. & Pavlova, A. (2006) Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia, 12(Suppl. 6), 15-22.
101. Pruthi, R.K., Mathew, P., Valentino, L.A., Sumner, M.J., Seremetis, S. & Hoots, W.K.; NovoSeven in Surgery Study Investigators. (2007) Haemostatic effect and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thrombosis and Haemostasis, 98, 710-712.
102. Quintana-Molina, M., Martínez-Bahamonde, F., González-García, E., Romero-Garrido, J., Villar-Camacho, A., Jiménez-Yuste, V., Fernández-Bello, I. & Hernández-Navarro, F. (2004) Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia, 10(Suppl. 2), 30-40.
103. Rangarajan, S., Yee, T.T. & Wilde, J. (2011) Experience of four UK comprehensive care centres using FEIBA for surgeries in patients with inhibitors. Haemophilia, 17, 28-34.
104. Recht, M., Pollmann, H., Tagliaferri, A., Musso, R., Janco, R. & Neuman, W.R. (2011) A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia, 17, 494-499.
105. Rocino, A. & de Biasi, R. (1999) Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients. Vox Sanguinis, 81, 35-38.
106. Rodríguez Merchan, E.C., Jiménez Yuste, V., GomezCardero, P., Alvarezroman, M., MartinSalces, M. & Rodríguez de La Rua, A. (2010) Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience. Haemophilia, 16, 84-88.
107. Rothschild, C., Laurian, Y., Satre, E.P., Borel Derlon, A., Chambost, H., Moreau, P., Goudemand, J., Parquet, A., Peynet, J., Vicariot, M., Beurrier, P., Claeyssens, S., Durin, A., Faradji, A., Fressinaud, E., Gaillard, S., Guérin, V., Guérois, C., Pernod, G., Pouzol, P., Schved, J.F. & Gazengel, C. (1998) French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis, 80, 779-783.
108. Sahud, M.A., Pratt, K.P., Zhukov, O., Qu, K. & Thompson, A.R. (2007) ELISA system for detection of immune responses to FVIII; a study of 246 samples and correlation with the Bethesda assay. Haemophilia, 13, 317-322.
109. Salaj, P., Brabec, P., Penka, M., Pohlreichova, V., Smejka, P., Cetkovsky, P., Dusek, L. & Hedner, U. (2009) Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia, 15, 752-759.
110. Santagostino, E., Mancuso, M.E., Rocino, A., Mancuso, G., Mazzucconi, M.G., Tagliaferri, A., Messina, M. & Mannucci, P.M. (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. British Journal of Haematology, 130, 422-427.
111. Santagostino, E., Mancuso, M.E., Rocino, A., Mancuso, G., Scaraggi, F. & Mannucci, P.M. (2006) A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. Journal of Thrombosis and Haemostasis, 4, 367-371.
112. Schneiderman, J., Rubin, E., Nugent, D.J. & Young, G. (2007) Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia, 13, 244-248.
113. Schulman, S., d'Oiron, R., Martinowitz, U., Pasi, J., Briquel, M.E., Mauser-Bunschoten, E., Morfini, M., Ritchie, B., Goudemand, J., Lloyd, J., McPherson, J., Négrier, C., Peerlinck, K., Petrini, P. & Tusell, J. (1998) Experiences with continuous infusion of recombinant activated factor VII. Blood Coagulation & Fibrinolysis, 9(Suppl. 1), 97-101.
114. Shapiro, A.D., Di Paola, J., Cohen, A., Pasi, K.J., Heisel, M.A., Blanchette, V.S., Abshire, T.C., Hoots, W.K., Lusher, J.M., Negrier, C., Rothschild, C. & Roth, D.A. (2005) The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood, 105, 518-525.
115. Smith, M.P., Spence, K.J., Waters, E.L., Berresford-Webb, R., Mitchell, M.J., Cuttler, J., Alhaq, S.A., Brown, A.A. & Savidge, G.F. (1999) Immune tolerance therapy for haemophilia A patients with acquired factor VIII antibodies: comprehensive analysis of experience at a single institution. Thrombosis and Haemostasis, 81, 35-38.
116. Smith, M.P., Ludlam, C.A., Collins, P.W., Hay, C.R., Wilde, J.T., Grigeri, A., Melsen, T. & Savidge, G.F. (2001) Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thrombosis and Haemostasis, 86, 949-953.
117. Sumner, M.J., Geldziler, B.D., Pedersen, M. & Seremetis, S. (2007) Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia, 13, 451-461.
118. Takedani, H., Kawahara, H. & Kajiwara, M. (2010) Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa. Haemophilia, 16, 290-295.
119. Teitel, J. & Poon, M.C. (2004) The safety of recombinant factor VIIa: a rebuttal. Journal of Thrombosis and Haemostasis, 2, 2078.
120. Teitel, J., Berntrop, E., Collins, P., D'Oiron, R., Ewenstein, B., Gomperts, E., Goudemand, J., Gringeri, A., Key, N., Leissinger, C., Monahan, P. & Young, G. (2007) A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia, 132, 256-263.
121. Teitel, J.M., Carcao, M., Lillicrap, D., Mulder, K., Rivard, G.E., St Louis, J., Smith, F., Walker, I. & Zourikian, N. (2009) Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia, 15, 227-239.
122. Ter Avest, P.C., Fischer, K., Gouw, S.C., Van Dijk, K. & Mauser-Bunschoten, E.P. (2010) Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia, 16, 71-79.
123. Thorland, E.C., Drost, J.B., Lusher, J.M., Warrier, I., Shapiro, A., Koerper, M.A., Dimichele, D., Westman, J., Key, N.S. & Sommer, S.S. (1999) Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia, 5, 101-105.
124. Tjønnfjord, G.E. (2004) Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia, 10(Suppl. 2), 41-45.
125. Valentino, L. (2004) FEIBA prophylaxis in hemophilia A patients with inhibitors results in 95% reduction in bleeding episodes. Abstract WFH Haemophilia.
126. Valentino, L.A. (2009) The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia, 15, 733-742.
127. van Veen, J.J., Gatt, A. & Makris, M. (2008) Thrombin generation testing in routine clinical practice: are we there yet? British Journal of Haematology, 142, 889-903.
128. Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., van Den Berg, M. & Mauser-Bunschoten, E. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis and Haemostasis, 73, 247-251.
129. Viel, K.R., Ameri, A., Abshire, T.C., Iyer, R.V., Watts, R.G., Lutcher, C., Channell, C., Cole, S.A., Fernstrom, K.M., Nakaya, S., Kasper, C.K., Thompson, A.R., Almasy, L. & Howard, T.E. (2009) Inhibitors of factor VIII in black patients with hemophilia. New England Journal of Medicine, 360, 1618-1627.
130. Warrier, I. (1998) Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia, 4, 574-576.
131. Warrier, I. & Lusher, J.M. (1998) Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagulation & Fibrinolysis, 9(Suppl. 1), S125-S128.
132. Warrier, I., Ewenstein, B.M., Koerper, M.A., Shapiro, A., Key, N., DiMichele, D., Miller, R.T., Pasi, J., Rivard, G.E., Sommer, S.S., Katz, J., Bergmann, F., Ljung, R., Petrini, P. & Lusher, J.M. (1997) Factor IX inhibitors and anaphylaxis in hemophilia B. Journal of Pediatric Hematology/oncology, 19, 23-27.